Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05188053 · ClinicalTrials.gov registry record · Phase 4
Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 209
- Enrollment target
NCT05188053: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT05188053 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 209 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05188053, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 209 participants
- Enrollment target
Study Summary
The purpose of this study is to compare an FDA-approved medication for post-operative pain control (HTX-011) to the standard of care institutional practice for periarticular analgesia after primary total knee arthroplasty (weight based dosing of Ropivacaine, epinephrine and ketorolac diluted with saline). We are doing this research study to find out if this new medication provides superior pain control within 72 hours following surgery.
Interventions
- DRUG HTX-011
- DRUG ropivacaine , epinephrine , ketorolac diluted in sodium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2024-04-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05188053
The ClinicalTrials.gov registry entry for NCT05188053 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HTX-011 is the first listed.
NCT05188053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05188053 about?
NCT05188053 is a clinical study titled "Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty". The purpose of this study is to compare an FDA-approved medication for post-operative pain control (HTX-011) to the standard of care institutional practice for periarticular analgesia after primary total knee arthroplasty (weight based dosing of Ropivacaine, epinephrine and ketorolac diluted with sa...
What is the current status of trial NCT05188053?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 209 participants. The study started on 2022-03-11. Estimated completion is 2024-04-18.
What interventions are being tested in trial NCT05188053?
The interventions under investigation include: HTX-011 (DRUG), ropivacaine , epinephrine , ketorolac diluted in sodium chloride (DRUG).
Who is sponsoring clinical trial NCT05188053?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.